148 related articles for article (PubMed ID: 15869845)
21. Validation of a behavioral health treatment outcome and assessment tool designed for naturalistic settings: The Treatment Outcome Package.
Kraus DR; Seligman DA; Jordan JR
J Clin Psychol; 2005 Mar; 61(3):285-314. PubMed ID: 15546147
[TBL] [Abstract][Full Text] [Related]
22. French version of the addiction severity index (5th Edition): validity and reliability among Swiss opiate-dependent patients. French validation of the Addiction Severity Index.
Krenz S; Dieckmann S; Favrat B; Spagnoli J; Leutwyler J; Schnyder C; Daeppen JB; Besson J
Eur Addict Res; 2004; 10(4):173-9. PubMed ID: 15367819
[TBL] [Abstract][Full Text] [Related]
23. Patterns and correlates of treatment: findings of the 2000-2001 NSW minimum dataset of clients of alcohol and other drug treatment services.
Copeland J; Indig D
Drug Alcohol Rev; 2004 Jun; 23(2):185-94. PubMed ID: 15370025
[TBL] [Abstract][Full Text] [Related]
24. Adverse drinking consequences among alcohol abusing intravenous drug users.
Anderson BJ; Gogineni A; Charuvastra A; Longabaugh R; Stein MD
Alcohol Clin Exp Res; 2001 Jan; 25(1):41-5. PubMed ID: 11198713
[TBL] [Abstract][Full Text] [Related]
25. Assessing past treatment history: test-retest reliability of the Treatment Response to Antidepressant Questionnaire.
Posternak MA; Young D; Sheeran T; Chelminski I; Franklin CL; Zimmerman M
J Nerv Ment Dis; 2004 Feb; 192(2):95-102. PubMed ID: 14770053
[TBL] [Abstract][Full Text] [Related]
26. Program monitoring for clinical practice. Specimen positivity across urine collection methods.
Moran J; Mayberry C; Kinniburgh D; James D
J Subst Abuse Treat; 1995; 12(3):223-6. PubMed ID: 7474030
[TBL] [Abstract][Full Text] [Related]
27. Reliabilities of short substance abuse screening tests among adolescent medical patients.
Knight JR; Goodman E; Pulerwitz T; DuRant RH
Pediatrics; 2000 Apr; 105(4 Pt 2):948-53. PubMed ID: 10742352
[TBL] [Abstract][Full Text] [Related]
28. The inventory of drug use consequences (InDUC): test-retest stability and sensitivity to detect change.
Tonigan JS; Miller WR
Psychol Addict Behav; 2002 Jun; 16(2):165-8. PubMed ID: 12079257
[TBL] [Abstract][Full Text] [Related]
29. Development and validation of a Client Problem Profile and Index for drug treatment.
Joe GW; Simpson DD; Greener JM; Rowan-Szal GA
Psychol Rep; 2004 Aug; 95(1):215-34. PubMed ID: 15460378
[TBL] [Abstract][Full Text] [Related]
30. [Factors influencing the adoption of hormone replacement therapy].
Légaré F; Dodin S; Godin G
Can Fam Physician; 1998 Jun; 44():1280-6. PubMed ID: 9640522
[TBL] [Abstract][Full Text] [Related]
31. Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA)--results of a Danish field trial.
Bilenberg N
Eur Child Adolesc Psychiatry; 2003 Dec; 12(6):298-302. PubMed ID: 14689262
[TBL] [Abstract][Full Text] [Related]
32. Psychometric properties of the Blood-borne Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ).
Fry CL; Lintzeris N
Addiction; 2003 Feb; 98(2):171-8. PubMed ID: 12534421
[TBL] [Abstract][Full Text] [Related]
33. Differences among out-of-treatment drug injectors who use stimulants only, opiates only or both: implications for treatment entry.
John D; Kwiatkowski CF; Booth RE
Drug Alcohol Depend; 2001 Oct; 64(2):165-72. PubMed ID: 11543986
[TBL] [Abstract][Full Text] [Related]
34. Consumer and service determinants of completion of a consumer self-rating outcome measure.
Trauer T
Australas Psychiatry; 2004 Mar; 12(1):48-54. PubMed ID: 15715739
[TBL] [Abstract][Full Text] [Related]
35. Substance abuse treatment policy implications derived from routine statistical reports.
Dasananjali T
Southeast Asian J Trop Med Public Health; 1999 Jun; 30(2):314-8. PubMed ID: 10774702
[TBL] [Abstract][Full Text] [Related]
36. New European instruments for treatment outcome research: reliability of the maudsley addiction profile and treatment perceptions questionnaire in Italy, Spain and Portugal.
Marsden J; Nizzoli U; Corbelli C; Margaron H; Torres M; Prada De Castro I; Stewart D; Gossop M
Eur Addict Res; 2000 Sep; 6(3):115-22. PubMed ID: 11060475
[TBL] [Abstract][Full Text] [Related]
37. The relative impact of waiting time and treatment entry on drug and alcohol use.
Best D; Noble A; Ridge G; Gossop M; Farrell M; Strang J
Addict Biol; 2002 Jan; 7(1):67-74. PubMed ID: 11900624
[TBL] [Abstract][Full Text] [Related]
38. The Portland Neurotoxicity Scale: validation of a brief self-report measure of antiepileptic-drug-related neurotoxicity.
Salinsky MC; Storzbach D
Assessment; 2005 Mar; 12(1):107-17. PubMed ID: 15695749
[TBL] [Abstract][Full Text] [Related]
39. Psychometric evaluation of the Customary Drinking and Drug Use Record (CDDR): a measure of adolescent alcohol and drug involvement.
Brown SA; Myers MG; Lippke L; Tapert SF; Stewart DG; Vik PW
J Stud Alcohol; 1998 Jul; 59(4):427-38. PubMed ID: 9647425
[TBL] [Abstract][Full Text] [Related]
40. Validation of the Christo Inventory for Substance-misuse Services (CISS): a simple outcome evaluation tool.
Christo G; Spurrell S; Alcorn R
Drug Alcohol Depend; 2000 May; 59(2):189-97. PubMed ID: 10891633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
